Detail akcie Indivior Pharma Rg online

Business Summary: Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Indivior Pharmaceuticals Inc revenues decreased 1% to $882M. Net income applicable to common stockholders totaled $106M vs. loss of $14M. Revenues reflect United States segment decrease of 2% to $745M. Net Income reflects Buprenorphine Based Drugs segment income increase from $75M to $181M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.10 to $0.85.